Known targets — ChEMBL curated mechanism
DHFRGARTPTGFRPTGIRPTGS1PTGS2TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8envmurAthyA
The experimentally established mechanism targets of Tromethamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | TNNC1 | P63316 | 5/20 | 0.30 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.30 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | GPR183 | P32249 | 1/20 | 0.30 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tromethamine SCHEMBL29175316 | 0.97 | MEN1 (0.67) | MEN1LMNAKMT2AS1PR1 | |
| Tromethamine SCHEMBL8497866 | 0.90 | MEN1 (0.67) | MEN1LMNAKMT2A | |
| Tromethamine SCHEMBL1532733 | 0.87 | MEN1 (0.62) | MEN1LMNAKMT2A | |
| Tromethamine SCHEMBL1278460 | 0.87 | MEN1 (0.62) | MEN1LMNAKMT2A | |
| Tromethamine SCHEMBL8772229 | 0.87 | MEN1 (0.62) | MEN1LMNAKMT2A | |
| Tromethamine SCHEMBL5655709 | 0.87 | MEN1 (0.62) | MEN1LMNAKMT2A | |
| Tromethamine SCHEMBL9443897 | 0.87 | MEN1 (0.62) | MEN1LMNAKMT2A | |
| Tromethamine SCHEMBL3433733 | 0.87 | MEN1 (0.62) | MEN1LMNAKMT2A | |
| Tromethamine SCHEMBL7193959 | 0.85 | MEN1 (0.83) | MEN1LMNAKMT2ATNNC1SGPL1 | |
| Tromethamine SCHEMBL28216031 | 0.85 | MEN1 (0.83) | MEN1LMNAKMT2ATNNC1SGPL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322777-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | PFIZER INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-11673890-B2 | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20210047325-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2021-02-18 | — | — | US | disclosed |
| US-10822335-B2 | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20190218218-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2019-07-18 | — | — | US | disclosed |
| US-9908883-B2 | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-20160347752-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2016-12-01 | — | — | US | disclosed |
| EP-2621493-B1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20160220557-A1 | USE OF ACETYL-COA CARBOXYLASE INHIBITORS FOR TREATING ACNE VULGARIS | PFIZER INC. (US) | 2016-08-04 | — | — | US | disclosed |
| EP-3043800-A1 | USE OF ACETYL-COA CARBOXYLASE INHIBITORS FOR TREATING ACNE VULGARIS | Pfizer Inc. (US) | 2016-07-20 | — | — | EP | disclosed |
| WO-2011058474-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20110111046-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | PFIZER INC | 2011-05-12 | — | — | US | disclosed |
| EP-0613467-A1 | 2-PYRIDINOL DERIVATIVES AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1994-09-07 | — | — | EP | disclosed |
| US-5292445-A | For polyamic acids containing water, solvent and a non-ionic base strong enough to deprotonate; coatings in electronics | AMOCO CORPORATION (US) | 1994-03-08 | — | — | US | disclosed |
| WO-1993010093-A1 | 2-PYRIDINOL DERIVATIVES AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1993-05-27 | — | — | WO | disclosed |
| WO-1993007137-A1 | PYRIDINOL DERIVATIVES AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1993-04-15 | — | — | WO | disclosed |
| EP-0171277-A2 | Improvements in or relating to tricycling quinoline derivatives | ELI LILLY AND COMPANY (US) | 1986-02-12 | — | — | EP | disclosed |
| US-4537964-A | Method of preparing permissibly-substituted 1H(and 2H)pyrazolo[3,4-g]quinolines; pyrimido[4,5,g]quinolines; thiazolo[4,5,g]quinolines and intermediates therefore | ELI LILLY AND COMPANY (US) | 1985-08-27 | — | — | US | disclosed |
| US-4537965-A | Method of preparing 4aR,8aR-5-permissibly substituted-6-oxo-octahydro-1H(and 2H)-pyrazolo[3,4-g]quinolines, useful as intermediates | ELI LILLY AND COMPANY (US) | 1985-08-27 | — | — | US | disclosed |
| US-4525584-A | HYPOTENSIVES | ELI LILLY AND COMPANY (US) | 1985-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322777-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | ACACA, ACACB, PC | MEN1 2376/4885LMNA 1522/4885KMT2A 1514/4885 |
| US-20160220557-A1 | USE OF ACETYL-COA CARBOXYLASE INHIBITORS FOR TREATING ACNE VULGARIS | ACACA, ACACB, ACAT2 | MEN1 4644/4885LMNA 4318/4885KMT2A 2262/4885 |
| US-11673890-B2 | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | ACACA, ACACB, PC | MEN1 2319/4885LMNA 1636/4885KMT2A 1554/4885 |
| US-20190218218-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | ACACA, ACACB, PC | MEN1 2376/4885LMNA 1591/4885KMT2A 1596/4885 |
| US-20110111046-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | ACACA, PC, ACACB | MEN1 2333/4885LMNA 2437/4885KMT2A 2366/4885 |
| US-20160347752-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | ACACA, ACACB, PC | MEN1 2376/4885LMNA 1522/4885KMT2A 1514/4885 |
| US-20210047325-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | ACACA, ACACB, PC | MEN1 2319/4885LMNA 1636/4885KMT2A 1554/4885 |
| US-10822335-B2 | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | ACACA, ACACB, PC | MEN1 2376/4885LMNA 1522/4885KMT2A 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.